We have previously used Epstein-Barr virus transformation to establish two clonal lymphoblastoid cell lines (48-1 and S-I) producing monoclonal antibodies against microtubular aggregates that appear in the hepatocytes of chimpanzees with non-A, non-B hepatitis (NANBH). To obtain additional antibodies directed against the same structure, the mouse hybridoma method was employed. Partially purified microtubular aggregates were prepared from liver homogenates of a chimpanzee with NANBH and used as the immunogen. Hybridoma cultures were first screened by radioimmunoassay against the partially purified antigen and secondly by immunofluorescence (IF) using liver sections from a chimpanzee with NANBH. Twenty-seven cultures exhibited positive IF reactions similar to those observed with the original antibodies, 48-1 and S-I, and were cloned by limiting dilution. The specificities of the monoclonal antibodies were tested by IF on liver biopsy specimens from chimpanzees with hepatitis A, B, D or NANBH and from normal chimpanzees. All the antibodies proved to be IgG. Immunoelectron microscopy revealed that all 27 antibodies bound to the same structure, the microtubular aggregates, in hepatocytes of chimpanzees with NANBH. To determine the size of the antigen polypeptide recognized by these antibodies, polyacrylamide gel electrophoresis and Western blot assays were performed. Nine of the 27 antibodies specifically reacted with a single polypeptide of Mr 44K (p44). The remaining 18 antibodies detected no antigen polypeptide on the filters. The anti-p44 antibodies were then tested using cross-competition assays with lzSI-labelled antibodies, and were found to be classifiable into three groups. In addition, the results indicate that at least three distinct epitopes are located on p44: epitope A recognized by group 1, epitope B recognized by group 2 and epitope C recognized by group 3.
INTRODUCTION
Despite world-wide efforts, to date no aetiological agent for non-A, non-B hepatitis (NANBH) has been identified, nor has a specific serological assay applicable to its diagnosis and screening been established (Bradley & Maynard, 1986; Sherlock, 1986) .
In searching for monoclonal antibodies (MAbs) associated with NANBH, we previously attempted to immortalize lymphoblasts in vitro using the Epstein-Barr virus transformation method. In this way, we established two clonal cell lines, 48-1 and S-l, that produced class IgM MAbs recognizing hepatocytes from NANBH virus-infected chimpanzees (Shimizu et al., 1985) . The 48-1 and S-1 MAbs reacted with liver biopsy specimens obtained from chimpanzees 0000-8415 O 1989 SGM with acute or chronic hepatitis caused by NANBH viruses, but not with biopsy tissues obtained from chimpanzees infected with either hepatitis A (HAV) or B (HBV) viruses, nor with material from normal chimpanzees.
Immunoelectron microscopy (IEM) revealed that both MAbs bound to the same hepatocyte structure, the microtubular aggregates which have previously been reported to be associated with NANBH (Pfeifer et al., 1980) . Recently, we found that these MAbs also react with liver tissues from hepatitis D virus (HDV)-infected chimpanzees (Shimizu et al., 1986) . Furthermore, immunoperoxidase staining showed that MAb 48-1 reacts with liver tissues from human patients with acute post-transfusion NANBH, while the S-1 MAb does not react at all with human livers (Y. K. Shimizu et al., unpublished data) .
To clarify the nature of the microtubular aggregates reacting with these antibodies further, we developed a radioimmunoassay (RIA); this enabled us to purify the antigen partially, from liver homogenates of chimpanzees with NANBH. A high degree of purification was, however, prevented by the unsuitability of the 48-1 and S-1 MAbs for the necessary assays, such as Western blotting. We have also been unsuccessful in developing an assay for the detection of serum-borne antibodies since the 48-1 and S-1 MAbs do not seem to work in a competitioninhibition RIA.
Thus, mouse hybridoma formation was employed in an effort to obtain new MAbs directed against the same structures and which could be used in the above-mentioned assays. We report here on the production of nine mouse MAbs capable of reacting with the antigen polypeptide electrophoretically blotted onto nitrocellulose filters. These MAbs will enable us to characterize the microtubular aggregate antigen further.
METHODS
Preparation of the antigen. Antigen material used for immunization was prepared from a liver homogenate from chimpanzee 34, which had been inoculated with the F strain of NANBH virus (Shimizu et al., 1979) , and had developed histological evidence of hepatitis, including intrahepatocytic formation of characteristic ultrastructures, i.e. tubular structures, microtubular aggregates and sponge-like inclusions (Pfeifer et al., 1980) . This chimpanzee died 8 weeks after inoculation, and after autopsy its liver was used to make the antigen preparation. The tissue was homogenized, and then clarified by centrifugation at 10000g for 60 min. The supernatant was recentrifuged at 100000g for 4 h through a 20~ (w/w) sucrose cushion, and the pellet thus formed was resuspended, layered onto a 10 to 60 % (w/w) sucrose density gradient (SDG), centrifuged at 77 000 g for 60 h, and then fractionated. The antigen activity of each fraction was assayed by a sandwich-type RIA using the S-1 antibody, and the peak fraction was used as the antigen preparation.
Immunization and fusion. A quantity (0.5 ml) of the SDG peak fraction, calculated retrospectively to contain approximately 10 ~tg of the antigen, was inoculated intraperitoneally into BALB/c mice with complete Freund's adjuvant. The mice were given a booster 1 month later, using an intravenous injection of 0.2 ml ofa 1 : 10 dilution of the same fraction. Spleen cells were isolated from immunized mice 3 days after the booster and fused with cells of the mouse myeloma line P3U1, using 50~ polyethylene glycol.
Screening. Hybridoma culture supernatants were screened for the presence of antibodies first by RIA against the SDG peak fraction and then by immunofluorescence (IF) using sections of liver tissue obtained from chimpanzee 34. Sections of liver tissue from uninfected chimpanzee 57 were used as a normal uninfected control. Cultures showing positive IF were cloned by limiting dilution, rescreened using IF, and then expanded. These MAbs were then tested by IEM for reactivity with the intrahepatocytic microtubular aggregates according to the method described previously (Shimizu et al., 1985) . Those antibodies capable of reacting with the denatured antigen polypeptide were finally screened using Western blot analysis.
Western blot analysis. The SDG peak fraction from chimpanzee 34 was separated by PAGE according to the method of Laemmli (1970) . Liver tissue from uninfected chimpanzee 57 was used as a control. After electrophoretic transfer of the antigen to nitrocellulose paper (Towbin et al., 1979) , each sheet was incubated in phosphate-buffered saline (PBS) containing 10~ (w/v) skimmed milk, and was then cut into strips. These were incubated with 4 lag IgG purified from each antibody preparation, washed in PBS containing 0.05~ Tween-20, incubated with a 1 : 500 dilution of peroxidase-labelled goat anti-mouse IgG (Cooper Biomedical), washed, and finally developed using 0.2 ~tg/ml 4-chloro-l-naphthol.
Cross-competition RIA. The wells of 96-well microplates were coated with 5 ktg of the S-1 MAb at 4 °C overnight. After blocking with PBS containing 5 ~ (w/v) bovine serum albumin, 50 ~tl of the partially purified antigen was added to each well and plates were incubated for 2 h at room temperature. Starting with a concentration of 50 ~tg/ml, 25 lal samples of a twofold dilution of competing unlabelled antibody were mixed with the same volume of ~2SI-labelled antibody (50000 c.p.m.). The mixtures were allowed to equilibrate, and after washing, the bound radioactivities were measured. The percentage competition was determined using the formula 100 (A -n)/A, where A is the c.p.m, in the absence of competing antibody, and n is the c.p.m, in its presence.
Infected liver specimens. All infected liver sections from chimpanzees were derived from experimental infection with NANBH agent strain F (no. 34, 60, 48 and 42) (Shimizu et aL, 1985) , HDV (no. 92 and 48) (Shimizu et al., 1986) , HBV or HAV at the glutamine-pyruvate transaminase peak during the acute phase. Sections from chimpanzees with NANB or HDV infection confirmed the positive reaction to 48-1 antibody observed in previous studies. Table 1 summarizes the results of the four fusion experiments; 1477 hybridoma cultures were tested by R I A against the partially purified antigen used for immunization, and 126 were found to be positive. Indirect I F using sections of livers from N A N B H virus-infected c h i m p a n z e e 34 and uninfected c h i m p a n z e e 57 was then performed. Twenty-seven out of the 126 cultures gave reactions similar to those obtained with the original antibodies, 48-1 and S-1. These 27 cultures were cloned by limiting dilution. All the antibodies were found by double diffusion tests to be IgG. Fig. 1 shows the cellular I F obtained with one of these 27 antibodies, M5. The staining was granular and located in the hepatocyte cytoplasm. To investigate the ultrastructural localization of the cytoplasmic antigens reacting with each MAb, IEM and standard thin-section electron microscopy (EM) were carried out on liver sections of chimpanzee 34. All antibodies recognized the same structure, the intrahepatocytic microtubular aggregates. As shown in Fig. 2 , the reaction products, indicating antibody binding, were localized to microtubular aggregates in the hepatocyte cytoplasm. Cytoplasmic tubular structures, known as type III alterations (Pfeifer et al., 1980) , were not stained. Fig. 3 shows the antibody-reactive microtubular aggregates observed by standard thin-section EM. These were morphologically identical to those originally described by Pfeifer et al. (1980) for chimpanzee NANBH.
RESULTS

Establishment and characterization of the MAbs
Antigen identification
The size of the polypeptide recognized by these 27 antibodies was analysed by SDS-PAGE and Western blotting. Nine of the 27 MAbs (M6, M15, M16, M17, M28, M39, M41, M42 and M43) specifically bound to a single polypeptide with an Mr of 44K (p44) (Fig. 4) , while the remaining 18 detected no antigen on the filters. The p44 was not detectable by SDS-PAGE in liver samples from the normal chimpanzee 57 and Western blot analysis revealed no bands (data not shown). These data strongly suggest that p44 is specifically produced in order to form the hepatocytic microtubular aggregates in the NANBH-bearing chimpanzees. To test the specificity of these nine antibodies for NANBH, IF tests were carried out on liver biopsy specimens from two chimpanzees experimentally infected with HAV, three chimpanzees infected with HBV, four chimpanzees infected with NANBH, two chimpanzees infected with HDV, and from six normal chimpanzees (Table 2 ). All the antibodies reacted in the same manner with liver biopsies from chimpanzees with either N A N B H or HDV, but not with those from chimpanzees with HAV or HBV, nor with tissues from normal chimpanzees. These results agree with those obtained for the 48-1 and S-1 antibodies. 
Analysis of the p44 epitopes
Epitope assignment of the nine anti-p44 antibodies was analysed by cross-competition assays, using competition between unlabelled and ~2SI-labelled antibodies. Table 3 summarizes the results. The antibodies were found to be classifiable into three groups: group 1 (M6, M16, M41, M42 and M43), group 2 (M28) and group 3 (M15, MI7 and M39). In addition, the results reveal that at least three contiguous epitopes are located on p44; epitope A was recognized by group 1, epitope B by group 2 and epitope C by group 3. Individual MAbs in each group exhibited over 80~ competition with each other and with the homologous antibody.
DISCUSSION
The present paper describes the establishment of nine clonal mouse hybridomas producing MAbs, shown by IEM to react with the microtubular aggregates of hepatocytes from chimpanzees, in a way similar to that observed with the original MAbs, 48-1 and S-1. All of the nine MAbs were demonstrated by Western blot analysis to react with the same polypeptide antigen, which had an Mr of 44K. The results of cross-competition assays reveal that the nine antibodies can be classified into three groups and that at least three distinct epitopes are located on the p44 antigen polypeptide: epitope A recognized by M6, M16, M41, M42 and M43, epitope B recognized by M28 and epitope C recognized by M 15, M 17 and M39. IF tests of chimpanzee liver tissues showed that all the anti-p44 antibodies react in the same manner with the liver biopsy specimens from chimpanzees with NANB or HDV, but do not react with tissues from chimpanzees with either HAV or HBV, nor with tissues from normal chimpanzees.
It is very interesting that these MAbs reacted with liver sections of two HDV-infected chimpanzees. Coinfection with NANBH virus is unlikely. Immunoperoxidase EM and Western blot analysis confirmed this result that HDV also induced the microtubular aggregates and p44 in the cytoplasm of infected hepatocytes (Y. K. Shimizu, unpublished observations). This finding suggests that p44 is one of the host-encoded proteins and is specifically induced by infection with HDV or NANBH.
In this study it was not determined whether there is a human liver antigen like the p44 of chimpanzee microtubular aggregates. It is possible, judging from the finding that microtubular aggregates have never been found in human liver hepatocytes, that the antigen is not the same as that found in chimpanzee livers. In order to answer this question, studies employing immunochemical and epidemiological research with human liver tissues are now in progress.
Utilizing the mouse MAbs described in this study, we have successfully purified the p44 antigen by reverse-phase high performance liquid chromatography, and have obtained its partial amino acid sequence (Y. Honda et al., unpublished data) . We have also used immunoscreening with these MAbs to isolate a cDNA-coded whole p44 protein from a liver specimen from a chimpanzee with NANBH (Takahashi et al., unpublished data) . A computerized search indicates that the p44 amino acid sequence does not resemble that of any proteins so far known. Details of these studies will be reported separately (Y. Honda et al., in preparation) . Further studies are now in progress to determine whether p44 and anti-p44 antibodies are detectable in human or chimpanzee serum, and to clarify whether their appearance has diagnostic implications.
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